Latest California Healthline Stories
An Alzheimer’s ‘Tsunami’ Threatens Latinos
The number of U.S. Latinos with the memory-robbing disease is expected to rise more than eightfold by 2060, to 3.5 million, according to a recent report — putting a strain on families and health care resources.
A Guide To Budget Reconciliation: The Byzantine Rules For Disassembling The Health Law
Republicans, who don’t have the votes to repeal the ACA directly, are hoping to use this strict budget strategy that requires only a majority vote to strip the health law of provisions they oppose.
Headaches Persist As Covered California Enrollment Nears End
Thousands of consumers have faced higher-than-expected premiums or lost their tax credits, at least temporarily, because of errors by the state’s health insurance exchange.
Republicans Standing Behind Price
KHN’s Julie Rovner is interviewed on WBUR’s “Here and Now” about the Senate Finance Committee’s hearing on the nomination of Rep. Tom Price to head HHS, as well as President Donald Trump’s recent executive order on the health law.
Sleeping Like A Baby Is A $325 Million Industry
Newborn sleep is a valuable commodity.
Sky-High Prices For Orphan Drugs Slam American Families And Insurers
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Una investigación de Kaiser Health News analiza las acciones de compañias farmacéuticas para manipular los precios de medicamentos huérfanos, utilizados para tratar enfermedades raras.
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
Orphan Drugs Interactive Database
Check out all the drugs the FDA has approved to treat rare diseases. You can search by brand name, or by disease, and see familiar names that were first sold on the mass market or all the drugs that won FDA approval to treat more than one rare disease.
Follow the twists and turns of the orphan drug industry over the past three decades.